Atlas Venture, a Cambridge, Mass.-based early stage venture capital firm investing in biotech innovation, added Rajesh (Raj) Devraj, PhD, to a venture partner role.
Devraj will be working with the Atlas team to identify and execute upon compelling opportunities for new biotechnology company creation.
With Atlas, Devraj co-founded and served as chief scientific officer of Disarm Therapeutics, which targeted SARM1 to treat diseases driven by axonal degeneration including MS and ALS and was acquired in 2020 by Eli Lilly for up to $1.36 billion including $135 million upfront. Before Disarm, he served as chief scientific officer of Atlas-founded Padlock Therapeutics until its acquisition by BMS for up to $600 million in 2016. Over a 25-year career in large pharma and biotech, Devraj has held senior leadership positions in drug discovery, early clinical development and strategic planning and has advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Devraj has also served on the boards of directors for several biotech companies.
Atlas Venture is a venture capital firm which has been building breakthrough biotech startups for over 25 years. The firm works side by side with scientists and entrepreneurs to translate high impact science into medicines for patients.